Synaptics Rises, Lumentum Falls, Acadia Pharma Jumps on Positive CHMP Drug Opinion
On this episode of Stock Movers:
Synaptics (SYNA) shares rise. Onsemi has agreed to buy Synaptics Inc. in an all-stock deal that values the company at about $6.2 billion. The transaction has a total enterprise value including debt of roughly $7 billion and is expected to close in mid-2027, subject to approvals.
Lumentum (LITE) shares fall. U.S. optical communication stocks dropped. This comes as Semiconductor stocks are broadly lower.
Acadia Pharma (ACAD) shares climb as much as 12%, the most intraday since May 2025, after the drugmaker said the European Medicines Agency’s CHMP issued a positive opinion for its drug to treat symptoms of Rett syndrome and recommended granting a marketing authorization.
See omnystudio.com/listener for privacy information.
You May Also Like

Bloomberg Talks
Bloomberg

ITM Trading Podcast
The Daniela Cambone Show and Taylor Made Economics

Marco Casario - Finanza Personale, Investimenti ed Economia
Marco Casario - Vois

Inversión Dividendos
Carlos García

Børsmorgen & Økonominyhetene
Finansavisen

How Money Works
How Money Works

Imagen Empresarial
Imagen Empresarial

Bloomberg Daybreak América Latina
Bloomberg
Company Interviews
Crux Investor

Proactive - Interviews for investors
Proactive
Community discussion